The New England Journal of Medicine | Research & Review ...
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
More Evidence and More Work to Do - The New England Journal …
Feb 28, 2024 · Several large studies then emerged documenting the presence of neurologic sequelae — including cognition and memory problems — in the postacute phase of SARS-CoV-2 infection. 2,3 A recent ...
Dapagliflozin in Patients with Chronic Kidney Disease
Sep 24, 2020 · The independent data monitoring committee recommended stopping the trial because of efficacy. Over a median of 2.4 years, a primary outcome event occurred in 197 of 2152 participants (9.2%) in the ...
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Aug 27, 2021 · In this double-blind trial, we randomly assigned 5988 patients with class II–IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in ...
Neoadjuvant Nivolumab plus Chemotherapy in Resectable ...
Apr 11, 2022 · Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens ...
Empagliflozin in Patients with Chronic Kidney Disease
Nov 4, 2022 · We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m 2 of body-surface area, or who had ...
Ribociclib plus Endocrine Therapy in Early Breast Cancer
Mar 20, 2024 · The NATALEE trial is a phase 3 trial comparing ribociclib plus endocrine therapy with endocrine therapy alone that was designed to test CDK4/6 inhibition in a broad population of patients with ...
Overall Survival with Pembrolizumab in Early-Stage Triple …
Sep 15, 2024 · We randomly assigned, in a 2:1 ratio, patients with previously untreated stage II or III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose ...
Pembrolizumab for Early Triple-Negative Breast Cancer
Feb 26, 2020 · High-risk early triple-negative breast cancer is frequently associated with early recurrence and high mortality. 1 Neoadjuvant chemotherapy is the preferred treatment approach. 2-4 In addition to ...
Microplastics and Nanoplastics in Atheromas and Cardiovascular …
Mar 6, 2024 · A total of 304 patients were enrolled in the study, and 257 completed a mean (±SD) follow-up of 33.7±6.9 months. Polyethylene was detected in carotid artery plaque of 150 patients (58.4%), with ...